home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 02/21/22

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

PDS0101 could become the first line therapy in HPV-16 associated cancers (40,500 cases/year in the U.S. or $6 billion/year revenue opportunity). The company has an enterprise value of just $125M. The stock has near-term catalysts this year and is at a good buy level. For fur...
PDSB - Catalyst watch for next week: Ford EV watch, Nikola earnings, Zendesk drama and Zuck talks AI/metaverse

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Febr...

PDSB - PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

The study evaluates PDS0101 with and without KEYTRUDA ® prior to surgery for HPV-associated oropharyngeal cancer FLORHAM PARK, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cance...

PDSB - PDS Biotech to further advance mid-stage trial for head and neck cancer after early win

PDS Biotechnology (NASDAQ:PDSB) announced it plans to fully enroll the VERSATILE-002 trial for PDS0101 in head and neck cancer after the Phase 2 study achieved its preliminary objective response benchmarks. The trial is designed to study PDS0101 in combination with Merck’s (NYSE:MRK) K...
PDSB - PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

FLORHAM PARK, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...

PDSB - PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

FLORHAM PARK, N.J., Jan. 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...

PDSB - PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference

FLORHAM PARK, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™...
PDSB - PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the ...

PDSB - PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

FLORHAM PARK, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that it h...

PDSB - PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference

FLORHAM PARK, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that its ...
Previous 10 Next 10